Is the concept to destroy the particles, pre-assembly or bind to circulating viral surface/spike proteins? I thought the latter...

I agree on the treatment window; the state of the testing landscape means many will have mild initial symptoms, recover, and then be hit with the immune disorders. At that point, trying to fight the virus is a bit late, and will likely need Leronlimab co-administered.

True... and it calls into question how it should be tested... each alone, then paired, then in full combination?

And Mt Sinai... yes I know several better.